
Opinion|Videos|August 23, 2024
Logistical and Access Challenges with CAR T-cell Therapy in R/R ALL
Experts in acute lymphoblastic leukemia examine the logistical challenges associated with CAR T-cell therapy delivery and assess the frequency of patient attrition due to manufacturing delays.
Advertisement
Video content above is prompted by the following:
- What are some logistical barriers with delivery of CAR T-cell Therapy?
- How frequently do your patients have to drop out from CAR T-cell therapy due to manufacturing time? How does it compare to the rates in the ZUMA-3 and FELIX Study?
- How feasible is it for your patients to remain in close proximity to the hospital per the REMS requirements?
- Have you observed any additional or unique access challenges in minority populations?
Advertisement
Related to this article

IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.

VGX-3100 met its composite primary end point in the phase 3 HPV-303CHN trial, supporting a nonsurgical treatment approach for HPV-16/18–associated cervical HSIL.

EVX-01 plus pembrolizumab generated sustained neoantigen-specific T-cell responses in advanced melanoma.

IDP-023 plus isatuximab was tolerable and generated responses in heavily pretreated relapsed/refractory multiple myeloma.

David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.

Longer follow-up of CAPItello-281 showed capivasertib plus abiraterone extended survival in PTEN-deficient hormone-sensitive prostate cancer.

Joshua J. Meeks, MD, PhD, explains how enfortumab vedotin plus pembrolizumab is reshaping organ preservation in MIBC.
Advertisement
Advertisement
Trending on OncLive
1
VGX-3100 Elicits Regression and Clearance in HPV-16/18–Associated Cervical HSILs
2
EVX-01 Plus Pembrolizumab Yields Neoantigen-Specific T-Cell Responses in Advanced Melanoma
3
IDP-023 Plus Isatuximab Drives Responses in Daratumumab-Refractory Multiple Myeloma
4
Canakinumab Reduces Nodule Size in High-Risk Lung Precancers
5

